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2-h glucose  
Traits Samples 
In silico follow-up 
analysis 
Ely (g) 
(n = 1722) 
EPIC-Norfolk (g) 
(n = 25,313) 
Fenland (g) 
(n = 6379) 
LOLIPOP (g) 
(n = 6565) 
ADDITION-Ely (g) 
(n = 932 T2D 






(FG: n = 20,077;  
2h glucose: n = 15,234) 
CHARGE Exome Chip analyses 
(FG n = 49,838;  
T2D cases = 9524,  
n controls = 60,718;  









(n = 3539) 
GEMs 
sequenced 
(n = 1579) 
Individuals with BMI 
sequenced (n = 11,806) 
Traits 
Samples 
Fasting glucose, 2 hour 
glucose, T2D, BMI 
Traits 
Samples 
Combined Analysis: Meta-analysis of discovery, follow-up and in silico follow-up analyses 
Fasting glucose, 2 hour 
glucose, T2D, BMI 
Variants with suggestive associations:   
p < 0.001 or in a target of interest to GSK 



























-0.15 (-0.20, -0.11) 
0.04 (-0.02, 0.10) 
0.02 (-0.01, 0.05) 
Beta (95% CI) 
    0 -0.3 -0.2 -0.1 0.1 0.2 0.3 










































2 h glucose 
Fasting insulin 
Body mass/BMI* 
Systolic blood pressure 
Diastolic blood pressure 

























































































































































0 -1.5 -1 -.5 -.25 .25 .5 
Lower with GLP1R agonist  
or carriage of 316Thr   
Higher with GLP1R agonist  
or carriage of 316Thr  
Standardized mean difference (95% CI) 
Effect of GLP1R agonists in non-diabetics 
Effect of GLP1R agonists in patients with Type 2 diabetes (T2D) 











































0.83 (0.76, 0.91) 
0.93 (0.87, 0.98) 
1.15 (0.82, 1.61) 
0.98 (0.73, 1.31) 
0.88 (0.70, 1.11) 
1.16 (0.91, 1.48) 
1.07 (0.80, 1.43) 
0.94 (0.81, 1.09) 
    1 0.7 0.8 0.9 1.2 1.4 1.6 



































































CoLaus,ELY,Fenland,LOLIPOP,	GEMS	 18,937	 -0.13	 0.04	 1.5x10
-3	
In	silico	
follow-up	 MAGIC	(29)	 20,077	 -0.16	 0.03	 1.1x10
-7-	
Combined	 		 40,883	 -0.15	 0.02	 2.6x10-10	
DPP4	 rs56179129	 2	 162890142	 V266I	 Fasting	glucose	 T	 C	 0.008	 Discovery	 GEMS	 1416	 0.61	 0.21	 3.6x10
-3	
		 		 		 		 		 		 		 		 		
Targeted	
follow-up	 CoLaus,ELY,LOLIPOP	 12934	 0.00	 0.07	 0.95	
		 		 		 		 		 		 		 		 		
In	silico	
follow-up	 CHARGE	Exome	chip	(18)	 49838	 0.00	 0.03	 0.16	
		 		 		 		 		 		 		 		 		 Combined	 		 64188	 0.01	 0.03	 0.71	
SLC5A1	 rs200410750	 22	 32439209	 5'	UTR	 Fasting	Glucose	 T	 C	 0.001	 Discovery	 Sequenced	and	imputed	CoLaus	 5210	 1.44	 0.33	 1.7x10
-5	
		 		 		 		 		 		 		 		 		
Targeted	
follow-up	 ELY,Fenland,LOLIPOP	 12707	 -0.16	 0.27	 0.56	
		 		 		 		 		 		 		 		 		
In	silico	
follow-up	 n/a	 		 		 		 NA	
		 		 		 		 		 		 		 		 		 Combined	 		 18059	 0.51	 0.19	 0.01	
CNR2	 rs4649124	 1	 24201357	 Synonymous	 2	hour	glucose	 A	 G	 0.420	 Discovery	 Sequenced	and	imputed	CoLaus	 505	 0.18	 0.06	 0.01	
		 		 		 		 		 		 		 		 		
Targeted	
follow-up	 ELY,Fenland	 6377	 0.00	 0.02	 0.95	
		 		 		 		 		 		 		 		 		
In	silico	
follow-up	 MAGIC	(proxy:	rs10917431)(49)		 15234	 -0.01	 0.01	 0.49	
		 		 		 		 		 		 		 		 		 Combined	 		 22106	 0.00	 0.01	 0.88	
CNR2	 rs2229579	 1	 24201162	 H316Y	 T2D	 T	 C	 0.110	 Discovery	 Sequenced	and	imputed	CoLaus	 385/5241	 0.73	 [0.55,0.97]	 0.03	
		 		 		 		 		 		 		 		 		
Targeted	
follow-up	 ADDITION-Ely,	NDS,LOLIPOP,GenOA	 7141/27096	 1.06	 [0.99,	1.14]	 0.07	
		 		 		 		 		 		 		 		 		
In	silico	
follow-up	 CHARGE	Exome	chip	(18)		 9524/60718	 0.96	 [0.90,	1.01]	 0.10	
		 		 		 		 		 		 		 		 		 Combined	 		 17047/93225	 0.99	 [0.95,	1.04]	 0.67	
	23	
	
HTR2C	 rs56372597	 X	 113951968	 Intronic	 BMI	 A	 G	 0.150	 Discovery	 BMI	 10798	 0.05	 0.02	 2.1x10
-3	




Fenland,	LOLIPOP	 36983	 0.00	 0.01	 0.92	
		 		 		 		 		 		 		 		 		
In	silico	
follow-up	 n/a	 		 		 		 NA	
		 		 		 		 		 		 		 		 		 Combined	 		 47781	 0.01	 0.01	 0.13	
MCHR1	 rs117372135	 22	 41075523	 T25M	 BMI	 T	 C	 0.002	 Discovery	 BMI	 10952	 0.62	 0.15	 4.5x10
-5	




CoLaus,ELY,EPIC,Fenland,LOLIPOP	 37240	 0.08	 0.10	 0.40	
		 		




working	group		 68978	 -0.04	 0.07	 0.59	
		 		 		 		 		 		 		 		 		 Combined	 		 117170	 0.08	 0.05	 0.13	
	
*Analyzed	in	sequenced	CoLaus	participants	only	owing	to	low	imputation	quality	(R2	<	0.5)	in	additional	CoLaus	participants	at	the	discovery	stage.	#Not	
analyzed	in	GEMS	due	to	low	number	of	carriers	(<	5	minor	alleles)	
